on Nanohale AG (isin : DE000A1EWVY8)
Formycon AG Extends CEO Contract and Joins Prime Standard
Formycon AG has announced the extension of CEO Dr. Stefan Glombitza's contract until 2027. This decision reflects the company's confidence in Dr. Glombitza's leadership, as he continues to guide the development of the biosimilar company. Dr. Glombitza has been pivotal in Formycon’s growth, leading to the approval of three biosimilars since joining the company in 2016.
Additionally, Formycon has received admission to the Prime Standard of the Frankfurt Stock Exchange, with trading set to begin on November 12, 2024. This move is expected to enhance Formycon's visibility with international investors and improve stock liquidity.
The Prime Standard requires high transparency, offering the company access to a broader investor base. Formycon’s strategic developments solidify its position in the biosimilar market, fostering further growth and international recognition.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news